CD274 and small cell lung carcinoma: In terms of response assessment, it has been shown that the neutrophil/lymphocyte ratio (NLR) value 6 weeks after anti-PD-1/PD-L1 antibody therapy appears to be a promising predictor of response in patients with small-cell lung cancer (Xiong et al., 2021).